Elanco Animal Health Inc. — 2021 Form 10-K
Reporting period: Fiscal year ended December 31, 2021. Although the request identifies 2021 Q4, this filing reports full-year results; separate fourth-quarter figures are not clearly provided in the supplied filing text. Unless otherwise noted, amounts are in millions of U.S. dollars.
Business context
Elanco is a global animal-health company selling products for pets and farm animals in more than 90 countries. It reports one operating segment. The 2021 results include a full year of Bayer Animal Health, acquired in August 2020, and KindredBio from its August 2021 acquisition.
Financial performance and position
| Metric | 2021 | 2020 | Change |
|---|---|---|---|
| Revenue | $4,765 | $3,273 | +46% |
| Cost of sales | $2,134 | $1,667 | +28% |
| Gross margin | 55% | 49% | +6 percentage points |
| R&D expense | $369 | $327 | +13% |
| Marketing, selling and administrative expense | $1,404 | $996 | +41% |
| Amortization of intangibles | $556 | $360 | +54% |
| Asset impairment, restructuring and other special charges | $628 | $623 | +1% |
| Interest expense | $236 | $150 | +57% |
| Net loss | $(472) | $(560) | Loss narrowed by $88 |
| Basic and diluted loss per share | $(0.97) | $(1.27) | Improved |
| Cash from operating activities | $483 | $(41) | Improved by $524 |
Pet Health revenue rose 73% to $2,351; Farm Animal revenue rose 27% to $2,332. Contract manufacturing contributed $82, or 2% of revenue. Elanco attributed most of the growth to acquired Bayer Animal Health revenue, with legacy-business growth also benefiting from recovery versus 2020 channel inventory reductions and pandemic-related demand weakness. Foreign exchange increased 2021 revenue by 1%.
Cash and cash equivalents were $638 at year-end, versus $495 in 2020. Total debt carrying value was $6,319, including $294 current; debt less cash was approximately $5,681. Current assets were $3,276 and current liabilities were $1,643. Capital expenditures were $126 and software purchases were $33. Operating cash flow less those two items was approximately $324; this is a simple derived measure, not a company-reported free-cash-flow metric.
Material changes and unusual items
- Revenue increased substantially with the first full-year contribution from Bayer Animal Health; its 2021 revenue contribution was $1,903, compared with $592 in 2020.
- Cost of sales fell to 45% of revenue from 51%, reflecting acquired product mix, manufacturing productivity, pricing and lower amortization of the Bayer inventory fair-value step-up.
- Net loss narrowed, but the company continued to report a loss. Special charges remained high at $628, including a $273 write-down of the Shawnee and Speke manufacturing-site disposal groups, $66 of intangible-asset impairments and restructuring and integration costs. Interest expense rose with acquisition-related borrowing.
- KindredBio was acquired for $444 cash consideration; $334 of acquired intangible assets was principally in-process R&D. The company launched eight products during 2021.
- Cash used in investing activities was $530, chiefly reflecting acquisition spending, including KindredBio. Financing activities provided $210, including new borrowing and repayments.
Outlook, risks and contingencies
The filing provides no quantified revenue or earnings guidance. Management expects 2022 capital expenditures and software purchases of approximately $155–$185 and says it believes liquidity is sufficient for planned needs and debt-covenant compliance. It also expects continued integration and productivity work; the timing and realization of synergies remain uncertain.
- Management cited ongoing COVID-19 uncertainty, supply-chain disruption, raw-material shortages, higher freight costs, labor constraints and inflationary pressure on customers and margins.
- Key business risks include intense competition and generic substitution; dependence on leading products; restrictions on farm-animal antibiotics; disease outbreaks; foreign-exchange exposure; and the success of product development and acquired-business integration. Seresto and the five leading products together represented 8% and 24% of 2021 revenue, respectively.
- Seresto faced U.S. putative class actions and an EPA petition seeking cancellation of its registration; the company said it stood behind the product’s safety and efficacy. A congressional subcommittee also requested information and sought temporary removal.
- The SEC issued a July 2021 subpoena concerning channel inventory and sales practices before mid-2020. The company said it was cooperating and believed its actions were appropriate. The outcomes of these matters were not predictable; no material litigation liability was recorded at year-end because no significant claim was considered both probable and estimable.
- Debt covenants and substantial indebtedness constrain flexibility. The company reported compliance with covenants at year-end. Its revolving-credit facility has financial maintenance tests, including a maximum net total leverage ratio of 7.71:1 and minimum interest coverage of 2.00:1.
- The company recorded a $62 tax charge associated with an increased valuation allowance on U.S. deferred tax assets. Goodwill was $6,172 and other intangible assets were $5,587, exposing reported results to future impairment judgments.
Most important facts for investors to verify
- How much of revenue growth and margin improvement reflects durable legacy-business performance versus acquisitions, channel comparisons and product mix.
- Progress on integration, cost savings, restructuring and the planned manufacturing-site sales; compare actual results with the expected $155–$185 of 2022 capital and software spending.
- Debt repayment, interest costs, covenant headroom and cash generation, particularly given the company’s losses and substantial debt.
- Developments in the Seresto litigation and EPA petition, and the SEC inquiry into historical channel inventory and sales practices.
- Whether product-pipeline launches, including KindredBio-derived candidates, achieve regulatory approval and commercial adoption; also monitor impairment risk in acquired goodwill and intangibles.